8-K current report · filed Nov 5, 2026

LifeStance Health Group, Inc. (LFST) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2LFST overview

Short answer

LifeStance Health Group, Inc. (LFST) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Third-quarter results announced for period ended September 30, 2026.

LifeStance Health Group, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter results announced for period ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, guidance and operating metrics
  • Results disclosure may affect valuation through updated performance trends and outlook

Item 7.01 · Regulation FD Disclosure

  • Exhibit 99.2 contains supplemental LifeStance Health Group information for investor review
  • Presentation details may provide additional operating or financial context beyond the 8-K filing

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $455.9M, up 25%, driven by 17% higher visits, clinician growth and improved revenue per visit
  • Net income $22.4M versus $1.1M, while Adjusted EBITDA rose 70% to $68.4M
  • Adjusted EBITDA margin expanded to 15.0% from 11.1%, signaling meaningful operating leverage
  • Clinician base reached 8,863, up 11%, with 321 net additions during Q3
  • FY 2026 outlook raised to revenue $1.741B-$1.761B and Adjusted EBITDA $242M-$250M; nine-month operating cash flow $170.0M

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $455.9M, up 25% year over year, with visits up 17% to 2.7M and clinicians up 11% to 8,863
  • Center Margin $161.4M, or 35.4%, versus 32.0% year over year, signaling improved delivery economics
  • Adjusted EBITDA $68.4M, margin 15.0%, versus $40.2M and 11.1% in Q3 2025
  • FY 2026 guidance raised: revenue $1,741M-$1,761M and Adjusted EBITDA $242M-$250M
  • Cash $218.8M versus $255.5M net long-term debt, while year-to-date share repurchases reached $122.4M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LifeStance Health Group, Inc. 8-K filings

Get the next LFST 8-K as it lands

Follow LFST for push alerts, or ask the research agent what this filing means.